Clinical trials are testing cancer drug rapamycin for Long COVID and ME

Clinical trials are testing cancer drug rapamycin for Long COVID and ME

Publication date: Jul 30, 2025

We also monitor blood levels for rapamycin itself to ensure it doesnt hit an immunosuppressive dose, said Putrino. They laughed me out of the room, said Alex in an interview. So, last summer, he went to a telehealth provider called Healthspan that specializes in supplying rapamycin for longevity. The difference in her physical limitations was night and day, she said. Among 40 people with ME taking low-dose rapamycin over three months, 29 (72. 5%) showed improvements in fatigue, post-exertional malaise, and orthostatic intolerance. But he couldnt find a physician who would prescribe rapamycin, a drug that was emerging as a study target for the disease. The trial is expected to conclude in November 2026. At high doses, rapamycin suppresses the immune system. Continuous use of rapamycin can also block another vital protein complex called mTORC2, leading to diabetes-like symptoms.

Concepts Keywords
Basketball Alex
Cancer Clinical
June Covid
Minimizing Dose
Nashville Drug
Long
Low
Months
Prescribing
Rapamycin
Said
Sick
Trial
Trials
Year

Semantics

Type Source Name
disease MESH orthostatic intolerance
pathway REACTOME Infectious disease
disease MESH infectious disease
disease MESH allergies
disease MESH T-cell exhaustion
pathway REACTOME Immune System
disease IDO quality
drug DRUGBANK Metformin
disease IDO blood
disease MESH viral infection
disease IDO protein
disease IDO process
disease IDO history
disease IDO bacteria
drug DRUGBANK Naltrexone
disease MESH infection
drug DRUGBANK Spinosad
pathway REACTOME Autophagy
disease MESH relapse
disease MESH Chronic Illness
disease MESH Long COVID
disease MESH myalgic encephalomyelitis
drug DRUGBANK Sirolimus
disease MESH cancer

Original Article

(Visited 5 times, 1 visits today)